Navigation Links
Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
Date:5/25/2011

n with gemcitabine.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Such statements include, but are not limited to, statements regarding our plans and goals, the expected properties and benefits of lesinurad, BAY 86-9766 (RDEA119) and our other compounds and the timing and results of our preclinical, clinical and other studies.  Risks that contribute to the uncertain nature of the forward-looking statements include risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, costs associated with our drug discovery and development programs, and risks related to the outcome of our business development activities, including collaboration or license agreements.  These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors."  All forward-looking statements contained in this press release speak only as of the date on which they were made.  We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

(Logo: http://photos.prnewswire.com/prnh/20091104/ARDEALOGO)


'/>"/>
SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)...  The need to add tissue preserving therapies ... prominently at the 108 th Annual Meeting ... Diego.  According to SonaCare Medical, a leader in ... the need for image-guided technologies to better identify ... minimally invasive ablative treatments, was addressed in the ...
(Date:5/23/2013)... 23, 2013  Every day, their baby stopped breathing, his ... lungs. April and Bryan Gionfriddo watched ... "Quite a few doctors said he had a ... April Gionfriddo , about her now 20-month-old son, ... work, we would take it and run with it." ...
(Date:5/23/2013)... Mass. , May 23, 2013  Hologic, ... HOLX ), a leading developer, manufacturer and supplier ... products, with an emphasis on serving the healthcare ... large-scale observational study in a U.S. clinical practice ... technology (breast tomosynthesis) with conventional 2D mammography alone ...
Breaking Medicine Technology:Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 2Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 3Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 4Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 5Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 6Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 4First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 2First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 4
... , , , , , , CAPUA, ... has entered into an agreement with Laboratoires Mayoly Spindler, Chatou ... has successfully completed process development and commenced cGMP manufacture of ... clinical needs. DSM BioSolutions manufactures the lipase compound at its ...
... , ALISO VIEJO, Calif., Dec. 21 Clarient, Inc. (Nasdaq: ... pathologists, oncologists and the pharmaceutical industry, today announced that it ... in an all-stock merger valued at up to $17.6 million, ... agreement are successfully met. As a result of the ...
Cached Medicine Technology:DSM to Manufacture 'MS1819' Lipase Compound for Mayoly Spindler 2DSM to Manufacture 'MS1819' Lipase Compound for Mayoly Spindler 3DSM to Manufacture 'MS1819' Lipase Compound for Mayoly Spindler 4Clarient Acquires Applied Genomics, Inc. 2Clarient Acquires Applied Genomics, Inc. 3Clarient Acquires Applied Genomics, Inc. 4Clarient Acquires Applied Genomics, Inc. 5Clarient Acquires Applied Genomics, Inc. 6Clarient Acquires Applied Genomics, Inc. 7
(Date:5/23/2013)... 23, 2013 Funeral Financials is encouraging ... to the EOD Memorial Foundation Funeral Financials ... greatest victims from the war. , According to ... 1941 before the U.S. was even at war. ... identified with the Explosive Ordnance Disposal Badge. EOD technicians ...
(Date:5/23/2013)... Da Vinci surgical robot maker Intuitive Surgical ... State May 23, according to Bloomberg.* The Rottenstein Law ... lawsuits , expresses disappointment in the ruling but encourages ... read a single verdict as representative of all da ... Taylor v. Intuitive Surgical Inc.; 09-2-03136-5, Superior Court, Port ...
(Date:5/23/2013)... Mann HealthDay Reporter , , THURSDAY, May 23 ... take to help treat hip and knee osteoarthritis may ... for developing glaucoma, a small new study of older ... an increase of intraocular pressure (IOP) or pressure inside ... leading causes of blindness. In the ...
(Date:5/23/2013)... THURSDAY, May 23 (HealthDay News) -- People who eat ... they realize -- and teens are the worst offenders, ... of calories in their meals by as much as ... as 23 percent, and adults by as much as ... in a news release from the Robert Wood Johnson ...
(Date:5/23/2013)... a woman harried by hot flashes says she,s having ... online in Menopause , the journal of The ... tests that what these women say about their memory ... that hot flashes were related to memory problems, and ... was a relationship between hot flashes and what women ...
Breaking Medicine News(10 mins):Health News:Funeral Financials Asks Americans to Donate their Memorial Day Beer Money to Help EOD Scholarship 2Health News:Funeral Financials Asks Americans to Donate their Memorial Day Beer Money to Help EOD Scholarship 3Health News:Da Vinci Surgical Robot Lawsuit News: Rottenstein Law Group LLP Comments on Intuitive Win in Negligent Training Trial 2Health News:Glucosamine Supplements Tied to Risk of Eye Condition 2Health News:Glucosamine Supplements Tied to Risk of Eye Condition 3Health News:How Many Calories in Your Fast-Food Meal? Guess Again 2
... NASHVILLE, Tenn. and GLEN ROCK, N.J., Aug. 6 ... of surveyed pharmacy directors say that by 2014 they ... preferred biologic for all immune conditions, such as rheumatoid ... the new Formulary Forum report entitled Formulary Advantages ...
... , , , , ... growing social network for physicians , announced today the addition ... to its leadership team. Mr. Chase joins iMedExchange as Vice President ... Pharmaceutical, Medical Device and Luxury Goods and Services companies. , ...
... , , JACKSONVILLE, Fla., Aug. ... most important of the five senses. Yet, new research reveals that across ... translates to good eye health. This and other findings confirm a large ... people from seeking proper treatment and diagnosis for them and their children. ...
... , , NEW YORK, Aug. 6 ... technology shown to significantly help improve the appearance of unwanted discoloration, ... through select physicians to help their patients achieve picture perfect skin. ... found in leading physician offices for $120 per 1 ounce pump. ...
... - Not for Release, Publication or Distribution Directly or Indirectly in, ... any Other Jurisdiction in Which Such Publication or Distribution ... is not a Prospectus and is not an Offer to Sell or a, ... United States or, in any Other Jurisdiction, , ...
... , , , ... ) today announced that its Board of Directors has named Daniel J. ... He will join Stereotaxis in September, 2009 and replace James M. ... Company effective at year end 2009. Mr. Johnston brings over 15 ...
Cached Medicine News:Health News:U.S. Payers Intend to Limit Preferred Coverage to Only One Immune Biologic 2Health News:U.S. Payers Intend to Limit Preferred Coverage to Only One Immune Biologic 3Health News:Former Microsoft Healthcare Executive Joins iMedExchange 2Health News:Worldwide Gap Between Vision Care Attitudes & Behavior 2Health News:Worldwide Gap Between Vision Care Attitudes & Behavior 3Health News:Worldwide Gap Between Vision Care Attitudes & Behavior 4Health News:Worldwide Gap Between Vision Care Attitudes & Behavior 5Health News:Photos: Lumixyl(TM) Enters the Market to Improve the Appearance of Hyperpigmentation without Irritation and Side Effects 2Health News:Photos: Lumixyl(TM) Enters the Market to Improve the Appearance of Hyperpigmentation without Irritation and Side Effects 3Health News:EANS-News: Alapis Announces its Share Capital Increase to Raise c. EUR 451.1 million 2Health News:EANS-News: Alapis Announces its Share Capital Increase to Raise c. EUR 451.1 million 3Health News:Stereotaxis Names Daniel Johnston as Chief Financial Officer 2Health News:Stereotaxis Names Daniel Johnston as Chief Financial Officer 3
Ultra-Slip™ endotracheal tube guide for single-patient use only., ,Caution: Not MRI Compatible....
FlexiSlip™ Plastic coated malleable metal core. Single use, Sterile, Latex Free. Soft distal tip flexes to reduce risk of trauma to patient. Malleable metal core is easy to shape. Low friction ...
Endotracheal Tube Stylet- Adult, Copper, Malleable, Non-Sterile, Latex Free, Suitable for tubes 5.0 mm I.D. or larger....
... Prevent dental and soft tissue damage. Used ... X-ray. Light-guided intubation is based upon the ... neck. This technique takes advantage of the ... the esophagus. A well-defined, circumscribed glow can ...
Medicine Products: